[Retracted] Efficacy, Safety, and Tumor Marker Inhibition of Apatinib Combined with Conventional Chemotherapy Regimens for Patients with Advanced Triple-Negative Breast Cancer

Table 1

The clinical efficacy between the conventional and combined groups after treatment.

Group	CR	PR	SD	PD	ORR	DCR
Conventional (n = 75)	2 (2.67%)	20 (26.67%)	29 (38.671%)	24 (32.00%)	22 (29.33%)	51 (68.00%)
Combined (n = 75)	6 (8.00%)	25 (33.33%)	30 (40.00%)	14 (18.67%)	31 (41.33%)^a	61 (81.33%)^a

^a compared with the conventional group.